Details der Publikation - Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period

Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period

Abstract Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma (SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years is rare. We report a patient who had a recurrence of both SCLC and LEMS after a 13-year DFS period. A 69-year-old man was diagnosed with LEMS and SCLC (cT0N2M0, stage IIIA) 13 years ago. Chemoradiotherapy was performed and a complete response was achieved. With anticancer treatment, the LEMS symptoms was alleviated. At the age of 82 years, gait disturbance appeared followed by left supraclavicular lymphadenopathy and further examination revealed the recurrence of SCLC. Careful screening for the recurrence of SCLC might be needed when the patient has recurrent or secondary paraneoplastic neurological syndrome even after a long DFS period..

Medienart:	E-Artikel

Erscheinungsjahr:	2016
Erschienen:	2016

Enthalten in:	Zur Gesamtaufnahme - volume:35
Enthalten in:	Chinese journal of cancer - 35(2016), 1 vom: 02. Juli

Sprache:	Englisch

Beteiligte Personen:	Asano, Fumio [VerfasserIn] Watanabe, Keisuke [VerfasserIn] Shinkai, Masaharu [VerfasserIn] Tei, Yoshitaka [VerfasserIn] Mishina, Kei [VerfasserIn] Tanabe, Mikiko [VerfasserIn] Ishii, Hiroshi [VerfasserIn] Shinoda, Masahiro [VerfasserIn] Shimokawaji, Tadasuke [VerfasserIn] Kudo, Makoto [VerfasserIn] Kaneko, Takeshi [VerfasserIn]

Links:	Volltext [kostenfrei]

Themen:	Lambert–Eaton myasthenic syndrome P/Q-type anti-voltage-gated calcium channel antibody Paraneoplastic neurological syndrome Paraneoplastic syndrome Small cell lung carcinoma

Anmerkungen:	© The Author(s) 2016

doi:	10.1186/s40880-016-0127-x

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	OLC2095609468

Internformat


LEADER	01000caa a22002652 4500
001	OLC2095609468
003	DE-627
005	20240325171305.0
007	cr uuu---uuuuu
008	230331s2016 xx \|\|\|\|\|o 00\| \|\|eng c
024	7		\|a 10.1186/s40880-016-0127-x \|2 doi
035			\|a (DE-627)OLC2095609468
035			\|a (DE-He213)s40880-016-0127-x-e
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
082	0	4	\|a 610 \|q VZ
084			\|a ASIEN \|q DE-1a \|2 fid
100	1		\|a Asano, Fumio \|e verfasserin \|4 aut
245	1	0	\|a Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period
264		1	\|c 2016
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a © The Author(s) 2016
520			\|a Abstract Lambert–Eaton myasthenic syndrome (LEMS) is a paraneoplastic syndrome and only 3% of small cell lung carcinoma (SCLC) patients have LEMS. Moreover, the recurrence of SCLC after a disease-free survival (DFS) of more than 10 years is rare. We report a patient who had a recurrence of both SCLC and LEMS after a 13-year DFS period. A 69-year-old man was diagnosed with LEMS and SCLC (cT0N2M0, stage IIIA) 13 years ago. Chemoradiotherapy was performed and a complete response was achieved. With anticancer treatment, the LEMS symptoms was alleviated. At the age of 82 years, gait disturbance appeared followed by left supraclavicular lymphadenopathy and further examination revealed the recurrence of SCLC. Careful screening for the recurrence of SCLC might be needed when the patient has recurrent or secondary paraneoplastic neurological syndrome even after a long DFS period.
650		4	\|a Lambert–Eaton myasthenic syndrome
650		4	\|a Paraneoplastic syndrome
650		4	\|a Paraneoplastic neurological syndrome
650		4	\|a P/Q-type anti-voltage-gated calcium channel antibody
650		4	\|a Small cell lung carcinoma
700	1		\|a Watanabe, Keisuke \|4 aut
700	1		\|a Shinkai, Masaharu \|4 aut
700	1		\|a Tei, Yoshitaka \|4 aut
700	1		\|a Mishina, Kei \|4 aut
700	1		\|a Tanabe, Mikiko \|4 aut
700	1		\|a Ishii, Hiroshi \|4 aut
700	1		\|a Shinoda, Masahiro \|4 aut
700	1		\|a Shimokawaji, Tadasuke \|4 aut
700	1		\|a Kudo, Makoto \|4 aut
700	1		\|a Kaneko, Takeshi \|4 aut
773	0	8	\|i Enthalten in \|t Chinese journal of cancer \|d BioMed Central, 1982 \|g 35(2016), 1 vom: 02. Juli \|h Online-Ressource \|w (DE-627)573090939 \|w (DE-600)2439836-6 \|w (DE-576)343627450 \|x 1944-446X \|7 nnns
773	1	8	\|g volume:35 \|g year:2016 \|g number:1 \|g day:02 \|g month:07
856	4	0	\|u https://dx.doi.org/10.1186/s40880-016-0127-x \|z kostenfrei \|3 Volltext
912			\|a GBV_USEFLAG_A
912			\|a SYSFLAG_A
912			\|a GBV_OLC
912			\|a FID-ASIEN
912			\|a SSG-OLC-PHA
912			\|a GBV_ILN_11
912			\|a GBV_ILN_20
912			\|a GBV_ILN_22
912			\|a GBV_ILN_23
912			\|a GBV_ILN_24
912			\|a GBV_ILN_31
912			\|a GBV_ILN_32
912			\|a GBV_ILN_39
912			\|a GBV_ILN_40
912			\|a GBV_ILN_60
912			\|a GBV_ILN_62
912			\|a GBV_ILN_63
912			\|a GBV_ILN_65
912			\|a GBV_ILN_69
912			\|a GBV_ILN_70
912			\|a GBV_ILN_73
912			\|a GBV_ILN_74
912			\|a GBV_ILN_90
912			\|a GBV_ILN_95
912			\|a GBV_ILN_100
912			\|a GBV_ILN_101
912			\|a GBV_ILN_105
912			\|a GBV_ILN_110
912			\|a GBV_ILN_120
912			\|a GBV_ILN_121
912			\|a GBV_ILN_138
912			\|a GBV_ILN_150
912			\|a GBV_ILN_151
912			\|a GBV_ILN_152
912			\|a GBV_ILN_161
912			\|a GBV_ILN_170
912			\|a GBV_ILN_171
912			\|a GBV_ILN_206
912			\|a GBV_ILN_213
912			\|a GBV_ILN_224
912			\|a GBV_ILN_230
912			\|a GBV_ILN_285
912			\|a GBV_ILN_293
912			\|a GBV_ILN_370
912			\|a GBV_ILN_374
912			\|a GBV_ILN_602
912			\|a GBV_ILN_636
912			\|a GBV_ILN_647
912			\|a GBV_ILN_2001
912			\|a GBV_ILN_2003
912			\|a GBV_ILN_2005
912			\|a GBV_ILN_2006
912			\|a GBV_ILN_2007
912			\|a GBV_ILN_2008
912			\|a GBV_ILN_2009
912			\|a GBV_ILN_2010
912			\|a GBV_ILN_2011
912			\|a GBV_ILN_2014
912			\|a GBV_ILN_2015
912			\|a GBV_ILN_2018
912			\|a GBV_ILN_2020
912			\|a GBV_ILN_2021
912			\|a GBV_ILN_2025
912			\|a GBV_ILN_2026
912			\|a GBV_ILN_2027
912			\|a GBV_ILN_2031
912			\|a GBV_ILN_2034
912			\|a GBV_ILN_2036
912			\|a GBV_ILN_2037
912			\|a GBV_ILN_2048
912			\|a GBV_ILN_2050
912			\|a GBV_ILN_2055
912			\|a GBV_ILN_2056
912			\|a GBV_ILN_2057
912			\|a GBV_ILN_2059
912			\|a GBV_ILN_2061
912			\|a GBV_ILN_2064
912			\|a GBV_ILN_2065
912			\|a GBV_ILN_2068
912			\|a GBV_ILN_2088
912			\|a GBV_ILN_2093
912			\|a GBV_ILN_2110
912			\|a GBV_ILN_2111
912			\|a GBV_ILN_2113
912			\|a GBV_ILN_2119
912			\|a GBV_ILN_2129
912			\|a GBV_ILN_2147
912			\|a GBV_ILN_2148
912			\|a GBV_ILN_2152
912			\|a GBV_ILN_2336
912			\|a GBV_ILN_2446
912			\|a GBV_ILN_2470
912			\|a GBV_ILN_2507
912			\|a GBV_ILN_2522
912			\|a GBV_ILN_2548
912			\|a GBV_ILN_2817
912			\|a GBV_ILN_4012
912			\|a GBV_ILN_4035
912			\|a GBV_ILN_4037
912			\|a GBV_ILN_4046
912			\|a GBV_ILN_4112
912			\|a GBV_ILN_4125
912			\|a GBV_ILN_4126
912			\|a GBV_ILN_4242
912			\|a GBV_ILN_4246
912			\|a GBV_ILN_4249
912			\|a GBV_ILN_4251
912			\|a GBV_ILN_4277
912			\|a GBV_ILN_4305
912			\|a GBV_ILN_4306
912			\|a GBV_ILN_4307
912			\|a GBV_ILN_4313
912			\|a GBV_ILN_4322
912			\|a GBV_ILN_4323
912			\|a GBV_ILN_4324
912			\|a GBV_ILN_4325
912			\|a GBV_ILN_4326
912			\|a GBV_ILN_4333
912			\|a GBV_ILN_4335
912			\|a GBV_ILN_4336
912			\|a GBV_ILN_4338
912			\|a GBV_ILN_4346
912			\|a GBV_ILN_4367
912			\|a GBV_ILN_4392
912			\|a GBV_ILN_4393
912			\|a GBV_ILN_4700
912			\|a GBV_ILN_4753
951			\|a AR
952			\|d 35 \|j 2016 \|e 1 \|b 02 \|c 07

Relapse of both small cell lung cancer and Lambert–Eaton myasthenic syndrome after a 13-year disease-free survival period

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände